Why Wegovy (semaglutide 2.4 mg) Causes Nausea: The Mechanism Explained

What does the Wegovy label say about the mechanism?

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1 [1]. It selectively binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake. The label also states that semaglutide delays gastric emptying [1]. Nausea is in the label's list of most common adverse reactions, defined as incidence of 5% or greater [1].

How common is nausea at 2.4 mg?

The label's table for Wegovy 2.4 mg weekly comes from three randomized, double-blind, placebo-controlled trials in 2,116 adults with obesity or overweight and 1,261 on placebo, treated for up to 68 weeks [1]. Nausea occurred in 44% versus 16%; vomiting in 24% versus 6%; diarrhea in 30% versus 16%; constipation in 24% versus 11%; and abdominal pain in 20% versus 10% [1]. Any GI reaction occurred in 73% versus 47% [1]. Treatment was stopped for adverse reactions in 6.8% versus 3.2%; nausea led to discontinuation in 1.8% versus 0.2%, vomiting in 1.2% versus 0%, and diarrhea in 0.7% versus 0.1% [1]. Severe GI adverse reactions were reported in 4.1% versus 0.9% [1].

Is delayed gastric emptying the cause?

The label establishes both effects, delayed gastric emptying and nausea as a common adverse reaction, but it does not say how much one contributes to the other [1]. What it does say is practical: start at 0.25 mg weekly and follow the dose escalation schedule to reduce the risk of gastrointestinal adverse reactions [1]. Slowed emptying can also change how oral medicines are absorbed, and the label advises closer monitoring for oral drugs with a narrow therapeutic index [1].

What does the label warn about?

The Wegovy label says use has been associated with gastrointestinal adverse reactions, sometimes severe, and that Wegovy is not recommended in patients with severe gastroparesis [1]. It warns about acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. Acute pancreatitis is a labeled warning; the label describes persistent severe abdominal pain, sometimes radiating to the back, that may or may not be accompanied by nausea or vomiting, and says to discontinue Wegovy if pancreatitis is suspected [1].